The role of topoisomerases and RNA transcription in the action of the antitumour benzonaphthyridine derivative SN 28049

Cancer Chemotherapy and Pharmacology

Volumn 62, Issue 5, 2008, Pages 753-762

  Bridewell, David J A ^a   Porter, Andrew C G ^b   Finlay, Graeme J ^a   Baguley, Bruce C ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

DACA; siRNA; Topo poisons; Topoisomerase; Transcription

Indexed keywords

DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); N (2 DIMETHYLAMINOETHYL) 4 ACRIDINECARBOXAMIDE; N [2 (DIMETHYLAMINO)ETHYL] 2,6 DIMETHYL 1 OXO 1,2 DIHYDROBENZO[B] 1,6 NAPHTHYRIDINE 4 CARBOXAMIDE; NAPHTHYRIDINE DERIVATIVE; SMALL INTERFERING RNA; SN 28049; UNCLASSIFIED DRUG; URIDINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENCY; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNA TRANSCRIPTION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL SURVIVAL; DNA TOPOISOMERASES, TYPE I; DNA TOPOISOMERASES, TYPE II; GENE EXPRESSION; GENES, REPORTER; HUMANS; LUCIFERASES; NAPHTHYRIDINES; PROTEIN SYNTHESIS INHIBITORS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNA, NEOPLASM; TETRACYCLINE; TRANSCRIPTION, GENETIC; URIDINE;

EID: 49749141511     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-007-0660-z     Document Type: Article

References (52)

1. JS Sebolt-Leopold JM English 2006 Mechanisms of drug inhibition of signalling molecules Nature 441 457 462
2. MW Van Dyke RP Hertzberg PB Dervan 1982 Map of distamycin, netropsin, and actinomycin binding sites on heterogeneous DNA: DNA cleavage-inhibition patterns with methidiumpropyl-EDTA.Fe(II) Proc Natl Acad Sci USA 79 5470 5474
3. J Shen JC Wang MW Van Dyke 2001 Identification of preferred actinomycin-DNA binding sites by the combinatorial method REPSA Bioorg Med Chem 9 2285 2293
4. BC Baguley 1991 DNA intercalating anti-tumour agents Anticancer Drug Des 6 1 35
5. M Sastry DJ Patel 1993 Solution structure of the mithramycin dimer-DNA complex Biochemistry 32 6588 6604
6. A Adams JM Guss CA Collyer WA Denny LP Wakelin 1999 Crystal structure of the topoisomerase II poison 9-amino-N-(2-dimethylamino)ethyl]acridine-4- carboxamide bound to the DNA hexanucleotide d(CGTACG)2 Biochemistry 38 9221 9233
7. A Adams JM Guss CA Collyer WA Denny AS Prakash LP Wakelin 2000 Acridinecarboxamide topoisomerase poisons: structural and kinetic studies of the DNA complexes of 5-substituted 9-amino-(N-(2-dimethylamino)ethyl)acridine-4- carboxamides Mol Pharmacol 58 649 658
8. A Adams JM Guss CA Collyer WA Denny LP Wakelin 2000 A novel form of intercalation involving four DNA duplexes in an acridine-4-carboxamide complex of d(CGTACG)(2) Nucleic Acids Res 28 4244 4253
9. C Twelves M Campone B Coudert M Van den Bent M de Jonge C Dittrich R Rampling R Sorio D Lacombe C de Balincourt P Fumoleau 2002 Phase II study of XR5000 (DACA) administered as a 120-h infusion in patients with recurrent glioblastoma multiforme Ann Oncol 13 777 780
10. CJ Twelves C Gardner A Flavin J Sludden I Dennis J de Bono P Beale P Vasey C Hutchison MA Macham A Rodriguez I Judson NM Bleehen 1999 Phase I and pharmacokinetic study of DACA (XR5000): a novel inhibitor of topoisomerase I and II. CRC Phase I/II Committee Br J Cancer 80 1786 1791
11. C Dittrich B Coudert L Paz-Ares F Caponigro M Salzberg T Gamucci X Paoletti C Hermans D Lacombe P Fumoleau 2003 Phase II study of XR 5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with non-small cell lung cancer Eur J Cancer 39 330 334
12. C Dittrich V Dieras P Kerbrat C Punt R Sorio F Caponigro X Paoletti C de Balincourt D Lacombe P Fumoleau 2003 Phase II study of XR5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with advanced ovarian cancer Invest New Drugs 21 347 352
13. F Caponigro C Dittrich JB Sorensen JH Schellens F Duffaud L Paz Ares D Lacombe C de Balincourt P Fumoleau 2002 Phase II study of XR 5000, an inhibitor of topoisomerases I and II, in advanced colorectal cancer Eur J Cancer 38 70 74
14. MR McCrystal BD Evans VJ Harvey PI Thompson DJ Porter BC Baguley 1999 Phase I study of the cytotoxic agent N-2-(dimethylamino)ethyl]acridine-4- carboxamide Cancer Chemother Pharmacol 44 39 44
15. GJ Finlay JF Riou BC Baguley 1996 From amsacrine to DACA (N-2-(dimethylamino)ethyl]acridine-4-carboxamide): selectivity for topoisomerases I and II among acridine derivatives Eur J Cancer 32A 708 714
16. DJ Bridewell GJ Finlay BC Baguley 1999 Mechanism of cytotoxicity of N-2-(dimethylamino)ethyl] acridine-4-carboxamide and of its 7-chloro derivative: the roles of topoisomerases I and II Cancer Chemother Pharmacol 43 302 308
17. GJ Finlay E Marshall JH Matthews KD Paull BC Baguley 1993 In vitro assessment of N-2-(dimethylamino)ethyl]acridine-4-carboxamide, a DNA-intercalating antitumour drug with reduced sensitivity to multidrug resistance Cancer Chemother Pharmacol 31 401 406
18. K Padget A Stewart P Charlton MJ Tilby CA Austin 2000 An investigation into the formation of N- [2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA) and 6-[2-(dimethylamino)ethylamino]- 3-hydroxy-7H-indeno[2, 1-C]quinolin-7-one dihydrochloride (TAS-103) stabilised DNA topoisomerase I and II cleavable complexes in human leukaemia cells Biochem Pharmacol 60 817 821
19. WA Denny BC Baguley 2003 Dual topoisomerase I/II inhibitors in cancer therapy Curr Top Med Chem 3 339 353
20. LW Deady T Rodemann L Zhuang BC Baguley WA Denny 2003 Synthesis and cytotoxic activity of carboxamide derivatives of benzo[b][1,6]naphthyridines J Med Chem 46 1049 1054
21. AJ Carpenter AC Porter 2004 Construction, characterization, and complementation of a conditional-lethal DNA topoisomerase IIalpha mutant human cell line Mol Biol Cell 15 5700 5711
22. M Gossen AL Bonin S Freundlieb H Bujard 1994 Inducible gene expression systems for higher eukaryotic cells Curr Opin Biotechnol 5 516 520
23. A Haldane GJ Finlay JB Gavin BC Baguley 1992 Unusual dynamics of killing of cultured Lewis lung cells by the DNA-intercalating antitumour agent N-2-(dimethylamino)ethyl]acridine-4-carboxamide Cancer Chemother Pharmacol 29 475 479
24. DJ Bridewell GJ Finlay BC Baguley 2001 Topoisomerase I/II selectivity among derivatives of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA) Anticancer Drug Des 16 317 324
25. F Li DC Altieri 1999 Transcriptional analysis of human survivin gene expression Biochem J 344 Pt 2 305 311
26. I Horikawa PL Cable C Afshari JC Barrett 1999 Cloning and characterization of the promoter region of human telomerase reverse transcriptase gene Cancer Res 59 826 830
27. T Aki S Yanagisawa H Akanuma 1997 Identification and characterization of positive regulatory elements in the human glyceraldehyde 3-phosphate dehydrogenase gene promoter J Biochem (Tokyo) 122 271 278
28. JL Nitiss J Zhou A Rose Y Hsiung KC Gale N Osheroff 1998 The bis(naphthalimide) DMP-840 causes cytotoxicity by its action against eukaryotic topoisomerase II Biochemistry 37 3078 3085
29. WK Eng L Faucette RK Johnson R Sternglanz 1988 Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of camptothecin Mol Pharmacol 34 755 760
30. BC Baguley L Zhuang E Marshall 1995 Experimental solid tumour activity of N-[2-(dimethylamino)ethyl]-acridine-4-carboxamide Cancer Chemother Pharmacol 36 244 248
31. K Wassermann J Markovits C Jaxel G Capranico KW Kohn Y Pommier 1990 Effects of morpholinyl doxorubicins, doxorubicin, and actinomycin D on mammalian DNA topoisomerases I and II Mol Pharmacol 38 38 45
32. AA Adjei M Charron EK Rowinsky PA Svingen J Miller JM Reid J Sebolt-Leopold MM Ames SH Kaufmann 1998 Effect of pyrazoloacridine (NSC 366140) on DNA topoisomerases I and II Clin Cancer Res 4 683 691
33. BH Long CE Willis AW Prestayko ST Crooke 1982 Effect of anthracycline analogues on the appearance of newly synthesized total RNA and messenger RNA in the cytoplasm of erythroleukemia cells Mol Pharmacol 22 152 157
34. JS Sebolt SV Scavone CD Pinter KL Hamelehle DD Von Hoff RC Jackson 1987 Pyrazoloacridines, a new class of anticancer agents with selectivity against solid tumors in vitro Cancer Res 47 4299 4304
35. HM Sobell 1985 Actinomycin and DNA transcription Proc Natl Acad Sci USA 82 5328 5331
36. M Ljungman F Zhang F Chen AJ Rainbow BC McKay 1999 Inhibition of RNA polymerase II as a trigger for the p53 response Oncogene 18 583 592
37. Y Arima M Nitta S Kuninaka D Zhang T Fujiwara Y Taya M Nakao H Saya 2005 Transcriptional blockade induces p53-dependent apoptosis associated with translocation of p53 to mitochondria J Biol Chem 280 19166 19176
38. FA Derheimer HM O'Hagan HM Krueger S Hanasoge MT Paulsen M Ljungman 2007 RPA and ATR link transcriptional stress to p53 Proc Natl Acad Sci USA 104 12778 12783
39. JJ Champoux 2001 DNA topoisomerases: structure, function, and mechanism Annu Rev Biochem 70 369 413
40. JC Wang 2002 Cellular roles of DNA topoisomerases: a molecular perspective Nat Rev Mol Cell Biol 3 430 440
41. DA Koster K Palle ES Bot MA Bjornsti NH Dekker 2007 Antitumour drugs impede DNA uncoiling by topoisomerase I Nature 448 213 217
42. A Merino KR Madden WS Lane JJ Champoux D Reinberg 1993 DNA topoisomerase I is involved in both repression and activation of transcription Nature 365 227 232
43. H Zhang JC Wang LF Liu 1988 Involvement of DNA topoisomerase I in transcription of human ribosomal RNA genes Proc Natl Acad Sci USA 85 1060 1064
44. E Pastwa E Ciesielska MK Piestrzeniewicz WA Denny M Gniazdowski L Szmigiero 1998 Cytotoxic and DNA-damaging properties of N-[2-(dimethylamino) ethyl]acridine-4-carboxamide (DACA) and its analogues Biochem Pharmacol 56 351 359
45. T Nagata M Higashigawa Y Shimono DC Cao X Yan Mao T M'Soka H Inamochi H Hori H Kawasaki M Sakurai 1998 Aclarubicin inhibits etoposide induced apoptosis through inhibition of RNA synthesis in P388 murine leukemic cells J Exp Clin Cancer Res 17 435 442
46. FA Derheimer CW Chang M Ljungman 2005 Transcription inhibition: a potential strategy for cancer therapeutics Eur J Cancer 41 2569 2576
47. A Rapisarda B Uranchimeg DA Scudiero M Selby EA Sausville RH Shoemaker G Melillo 2002 Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway Cancer Res 62 4316 4324
48. A Mialon M Sankinen H Soderstrom TT Junttila T Holmstrom R Koivusalo AC Papageorgiou RS Johnson S Hietanen K Elenius J Westermarck 2005 DNA topoisomerase I is a cofactor for c-Jun in the regulation of epidermal growth factor receptor expression and cancer cell proliferation Mol Cell Biol 25 5040 5051
49. I Collins A Weber D Levens 2001 Transcriptional consequences of topoisomerase inhibition Mol Cell Biol 21 8437 8451
50. C Punchihewa A De Alba N Sidell D Yang 2007 XR5944: a potent inhibitor of estrogen receptors Mol Cancer Ther 6 213 219
51. S Safe M Abdelrahim 2005 Sp transcription factor family and its role in cancer Eur J Cancer 41 2438 2448
52. AR Black JD Black J Azizkhan-Clifford 2001 Sp1 and kruppel-like factor family of transcription factors in cell growth regulation and cancer J Cell Physiol 188 143 160